Skip to main content

anti-egfr/anti-c-met monoclonal antibody fpi-2053

Generic: Anti-EGFR/Anti-c-Met Monoclonal Antibody FPI-2053

anti-egfr/anti-c-met monoclonal antibody fpi-2053: 2 clinical trials tracked.

anti-egfr/anti-c-met monoclonal antibody fpi-2053 evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about anti-egfr/anti-c-met monoclonal antibody fpi-2053, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence5 indications · 1 study sponsors
Clinical Trial Registry Records (2)

A Phase I Multicentre Open-label Study to Evaluate Safety, Tolerability, and Dosimetry of [111In]-FPI-2107 in Chinese Adult Participants With EGFR Mutation-positive NSCLC

NCT07500987Registry updated 2026-09-11·Phase 1·AZN
Terminated

Primary endpoint: Safety and tolerability of [111In]-FPI 2107 following the administration of FPI 2053

Interventionalopen6 enrolledStarted 2026-02Completion 2026-053 sites · ChinaAstraZeneca

A Phase 1, First-in-human, Multicentre, Open-label, Dose Escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

NCT06147037Registry updated 2026-09-30·Phase 1·AZN
Active, not recruiting

Primary endpoint: Evaluate safety and tolerability of [111In]-FPI-2107, FPI-2053, and [225Ac]-FPI-2068

Interventionalopen13 enrolledStarted 2024-07Completion 2026-128 sites · Canada, United StatesAstraZeneca